Marco is part of the Research External Innovation team at CSL, based in Bern. He is responsible for identifying and evaluating new project and product opportunities to support CSL’s portfolio. He also focuses on building academic and early-stage collaborations and networks. Marco received his Diploma and PhD in the field of immunology from the University of Basel in Switzerland, where he patented a pneumococcal vaccine. After two years of working with antibody display and nanobody therapeutics at the Whitehead Institute for Biomedical Research in Cambridge (USA), he joined the University of Freiburg im Breisgau and Max Planck Institute of Immunobiology and Epigenetics in Germany. There he led research projects focused on CRISPR engineering, chimeric antigen receptors, and immunometabolism while he also taught immunology to students and was co-responsible for the immunology curriculum. During his academic career, he co-founded several academic networks especially for junior researchers such as ‘Friends of Basel – swissnex’, UniCliMax, and DGfI Young Immuno Investigators (YII). Prior to joining CSL, he also worked as an academic science consultant for the pharmaceutical industry.